Key result
Platelet aggregation was normal in coagulation factor deficiencies and thrombosis, but impaired in specific platelet defects, uraemia, and certain leukaemias.
Why the study?
Does the rate of platelet aggregation differ between healthy subjects and patients with haemorrhagic disease or thrombosis?
Population
Healthy subjects, patients with haemorrhagic diseases, patients on phenindione or heparin, and patients with…
Comparison
In vitro platelet aggregation testing using a… vs Healthy subjects.
Design
Cross-sectional
Authors
Loading...
Supports selective aggregation testing in suspected platelet disorders; leaves open its value in thrombosis and requires prospective validation.
Observational
Does the rate of platelet aggregation differ between healthy subjects and patients with haemorrhagic disease or thrombosis?
The study demonstrates that impaired platelet aggregation is associated with specific platelet or plasma defects rather than coagulation factor deficiencies, and finds no evidence of increased aggregation in arterial or venous thrombosis.
OZENBERG et al. (1966) conducted an observational in Haemorrhagic disease and thrombosis. Haemorrhagic disease and thrombosis vs. Healthy subjects was evaluated on Rate of platelet aggregation. Platelet aggregation was normal in coagulation factor deficiencies and thrombosis, but impaired in specific platelet defects, uraemia, and certain leukaemias.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: